In particular, high-grade gliomas are characterized by a large heterogeneity that affects treatment prognosis, and further studies are needed to clarify what advantage SDT might have for a better prognosis, e.g., for patients with MGMT-positive or -negative status. The gene discussed is MGMT; the disease is glioma.